Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

Bone Marrow Transplantation volume 51, pages 1041–1049 (2016)Cite this article

Subjects

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are under-recognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 348–371.

    PubMed  Google Scholar 

  2. Fuji S, Einsele H, Savani BN, Kapp M . Systematic nutritional support in allogeneic HSCT recipients. Biol Blood Marrow Transplant 2015; 21: 1707–1713.

    PubMed  Google Scholar 

  3. Geiss LS, Wang J, Cheng YJ, Thompson TJ, Barker L, Li Y et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. JAMA 2014; 312: 1218–1226.

    CAS  PubMed  Google Scholar 

  4. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014; 311: 1778–1786.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Jenssen T, Hartmann A . Emerging treatments for post-transplantation diabetes mellitus. Nat Rev Nephrol 2015; 11: 465–477.

    CAS  PubMed  Google Scholar 

  6. Sharif A . Treatment options for post-transplantation diabetes mellitus. Curr Diabetes Rev 2015; 11: 155–162.

    CAS  PubMed  Google Scholar 

  7. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506–1514.

    CAS  PubMed  Google Scholar 

  8. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC . Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Angelopoulos TP, Tentolouris NK, Bertsias GK, Boumpas DT . Steroid-induced diabetes in rheumatologic patients. Clin Exp Rheumatol 2014; 32: 126–130.

    PubMed  Google Scholar 

  10. Magee MH, Blum RA, Lates CD, Jusko WJ . Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001; 41: 1180–1194.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Toth GG, Kloosterman C, Uges DR, Jonkman MF . Pharmacokinetics of high-dose oral and intravenous dexamethasone. Ther Drug Monit 1999; 21: 532–535.

    CAS  PubMed  Google Scholar 

  12. Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ . Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1100–1107.

    CAS  PubMed  Google Scholar 

  13. Paris C, Yates L, Lama P, Zepeda AJ, Gutierrez D, Palma J . Evaluation of metabolic syndrome after hematopoietic stem cell transplantation in children and adolescents. Pediatr Blood Cancer 2012; 59: 306–310.

    PubMed  Google Scholar 

  14. Majhail NS, Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009; 43: 49–54.

    CAS  PubMed  Google Scholar 

  15. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M . Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000; 356: 993–997.

    CAS  PubMed  Google Scholar 

  16. Bizzarri C, Pinto RM, Ciccone S, Brescia LP, Locatelli F, Cappa M . Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation. Pediatr Blood Cancer 2015; 62: 1650–1655.

    CAS  PubMed  Google Scholar 

  17. Hirabayashi K, Nakazawa Y, Matsuura H, Hara Y, Kurata T, Hirabayashi K et al. Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies. Int J Hematol 2014; 99: 477–486.

    CAS  PubMed  Google Scholar 

  18. Baker KS, Chow E, Goodman P, Koves I, Leisenring W, Hoffmeister P et al. Adverse impact of hematopoietic cell transplantation (HCT) on body composition and insulin resistance (IR) is associated with increased cardiovascular risk. Biol Blood Marrow Transplant 2011; 17: S174–S175.

    Google Scholar 

  19. Baker KS, Chow E, Steinberger J . Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 619–625.

    CAS  PubMed  Google Scholar 

  20. Neville KA, Cohn RJ, Steinbeck KS, Johnston K, Walker JL . Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors. J Clin Endocrinol Metab 2006; 91: 4401–4407.

    CAS  PubMed  Google Scholar 

  21. Pham TM, Ekwaru JP, Setayeshgar S, Veugelers PJ . The effect of changing serum 25-hydroxyvitamin D concentrations on metabolic syndrome: a longitudinal analysis of participants of a preventive health program. Nutrients 2015; 7: 7271–7284.

    PubMed  PubMed Central  Google Scholar 

  22. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C et al. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 2011; 86: 954–956.

    CAS  PubMed  Google Scholar 

  23. Robien K, Strayer LG, Majhail N, Lazovich D, Baker KS, Smith AR et al. Vitamin D status among long-term survivors of hematopoietic cell transplantation. Bone Marrow Transplant 2011; 46: 1472–1479.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Benrashid M, Moyers K, Mohty M, Savani BN . Vitamin D deficiency, autoimmunity, and graft-versus-host-disease risk: Implication for preventive therapy. Exp Hematol 2012; 40: 263–267.

    CAS  PubMed  Google Scholar 

  25. Henden AS, Hill GR . Cytokines in graft-versus-host disease. J Immunol 2015; 194: 4604–4612.

    CAS  PubMed  Google Scholar 

  26. DiCarlo J, Agarwal-Hashmi R, Shah A, Kim P, Craveiro L, Killen R et al. Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 2014; 20: 361–369.

    CAS  PubMed  Google Scholar 

  27. Airaghi L, Usardi P, Forti S, Orsatti A, Baldini M, Annaloro C et al. A comparison between metabolic syndrome post-hematopoietic stem cell transplantation and spontaneously occurring metabolic syndrome. J Endocrinol Invest 2011; 34: e6–11.

    CAS  PubMed  Google Scholar 

  28. Chow EJ, Simmons JH, Roth CL, Baker KS, Hoffmeister PA, Sanders JE et al. Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant 2010; 16: 1674–1681.

    PubMed  PubMed Central  Google Scholar 

  29. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853.

  30. Sharif A, Hecking M, de Vries AP, Porrini E, Hornum M, Rasoul-Rockenschaub S et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant 2014; 14: 1992–2000.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D . New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care 2012; 35: 181–188.

    CAS  PubMed  Google Scholar 

  32. Sharif A, Moore RH, Baboolal K . The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: An underdiagnosed phenomenon. Transplantation 2006; 82: 1667–1672.

    PubMed  Google Scholar 

  33. Dagogo-Jack S . Pitfalls in the use of HbA(1)(c) as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol 2010; 6: 589–593.

    CAS  PubMed  Google Scholar 

  34. Healy SJ, Dungan KM . Hyperglycemia in patients with hematologic malignancies. Curr Diab Rep 2015; 15: 8.

    PubMed  Google Scholar 

  35. Koh GC, Peacock SJ, van der Poll T, Wiersinga WJ . The impact of diabetes on the pathogenesis of sepsis. Eur J Clin Microbiol Infect Dis 2012; 31: 379–388.

    CAS  PubMed  Google Scholar 

  36. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829–841.

    CAS  Google Scholar 

  37. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT . Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 2008; 31: 1541–1545.

    PubMed  PubMed Central  Google Scholar 

  38. Bertoni AG, Saydah S, Brancati FL . Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 2001; 24: 1044–1049.

    CAS  PubMed  Google Scholar 

  39. Wolfe F, Caplan L, Michaud K . Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628–634.

    CAS  PubMed  Google Scholar 

  40. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010; 69: 380–386.

    CAS  PubMed  Google Scholar 

  41. Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S et al. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2015; 41: 1141–1148.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Caira M, Candoni A, Verga L, Busca A, Delia M, Nosari A et al. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica 2015; 100: 284–292.

    PubMed  PubMed Central  Google Scholar 

  43. Penfornis A, Kury-Paulin S . Immunosuppressive drug-induced diabetes. Diabetes Metab 2006; 32: 539–546.

    CAS  PubMed  Google Scholar 

  44. Sharif A, Baboolal K . Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol 2012; 8: 34–42.

    CAS  Google Scholar 

  45. Hayer MK, Farrugia D, Begaj I, Ray D, Sharif A . Infection-related mortality is higher for kidney allograft recipients with pretransplant diabetes mellitus. Diabetologia 2014; 57: 554–561.

    PubMed  Google Scholar 

  46. Wyzgal J, Paczek L, Ziolkowski J, Pawlowska M, Rowinski W, Durlik M . Early hyperglycemia after allogenic kidney transplantation. Ann Transplant 2007; 12: 40–45.

    CAS  PubMed  Google Scholar 

  47. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ . Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178–185.

    PubMed  Google Scholar 

  48. Cole EH, Johnston O, Rose CL, Gill JS . Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3: 814–821.

    PubMed  PubMed Central  Google Scholar 

  49. Valderhaug TG, Hjelmesaeth J, Jenssen T, Roislien J, Leivestad T, Hartmann A . Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. Transplantation 2012; 94: 714–720.

    CAS  PubMed  Google Scholar 

  50. Hosseini MS, Nemati E, Pourfarziani V, Taheri S, Nourbala MH, Einollahi B . Early hyperglycemia after allogenic kidney transplantation: does it induce infections. Ann Transplant 2007; 12: 23–26.

    PubMed  Google Scholar 

  51. Griffith ML, Jagasia MH, Misfeldt AA, Chen H, Engelhardt BG, Kassim A et al. Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 86–92.

    CAS  PubMed  Google Scholar 

  52. Engelhardt BG, Jagasia SM, Crowe JE Jr., Griffith ML, Savani BN, Kassim AA et al. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Blood 2012; 119: 2417–2421.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Rassias AJ, Marrin CA, Arruda J, Whalen PK, Beach M, Yeager MP . Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg 1999; 88: 1011–1016.

    CAS  PubMed  Google Scholar 

  54. Hecking M, Haidinger M, Doller D, Werzowa J, Tura A, Zhang J et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23: 739–749.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Keddis MT, El Ters M, Rodrigo E, Dean P, Wohlfahrtova M, Kudva YC et al. Enhanced posttransplant management of patients with diabetes improves patient outcomes. Kidney Int 2014; 86: 610–618.

    PubMed  Google Scholar 

  56. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Takano K, Fuji S, Uchida N, Ogawa H, Ohashi K, Eto T et al. Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT. Bone Marrow Transplant 2015; 50: 553–558.

    CAS  PubMed  Google Scholar 

  58. Radfar M, Faghihi T, Hadjibabaie M, Ebrahimi F, Qorbani M, Iravani M et al. Impact of preexisting diabetes mellitus on transplantation outcomes in hematopoietic stem cell transplantation. Endocr Res 2015; 40: 20–24.

    PubMed  Google Scholar 

  59. Goldberg RB . Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009; 94: 3171–3182.

    CAS  PubMed  Google Scholar 

  60. Fuji S, Yakushijin K, Kim SW, Yoshimura K, Kurosawa S, Fukuda T . Dynamic change of glycemic status during the early phase after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2015; 50: 1473–1475.

    CAS  PubMed  Google Scholar 

  61. Hammer MJ, Casper C, Gooley TA, O'Donnell PV, Boeckh M, Hirsch IB . The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2009; 15: 344–351.

    PubMed  PubMed Central  Google Scholar 

  62. Fuji S, Kim SW, Mori S, Fukuda T, Kamiya S, Yamasaki S et al. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. Transplantation 2007; 84: 814–820.

    PubMed  Google Scholar 

  63. Derr RL, Hsiao VC, Saudek CD . Antecedent hyperglycemia is associated with an increased risk of neutropenic infections during bone marrow transplantation. Diabetes Care 2008; 31: 1972–1977.

    PubMed  PubMed Central  Google Scholar 

  64. Gebremedhin E, Behrendt CE, Nakamura R, Parker P, Salehian B . Severe hyperglycemia immediately after allogeneic hematopoietic stem-cell transplantation is predictive of acute graft-versus-host disease. Inflammation 2013; 36: 177–185.

    CAS  PubMed  Google Scholar 

  65. Sheean PM, Freels SA, Helton WS, Braunschweig CA . Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 656–664.

    PubMed  Google Scholar 

  66. Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J et al. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biol Blood Marrow Transplant 2011; 17: 239–248.

    CAS  PubMed  Google Scholar 

  67. Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007; 110: 3463–3471.

    CAS  PubMed  Google Scholar 

  68. Tichelli A, Passweg J, Wojcik D, Rovo A, Harousseau JL, Masszi T et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93: 1203–1210.

    PubMed  Google Scholar 

  69. Chow EJ, Mueller BA, Baker KS, Cushing-Haugen KL, Flowers ME, Martin PJ et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 2011; 155: 21–32.

    PubMed  Google Scholar 

  70. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359–1367.

    CAS  PubMed  Google Scholar 

  71. Langouche L, Vanhorebeek I, Van den Berghe G . Therapy insight: the effect of tight glycemic control in acute illness. Nat Clin Pract Endocrinol Metab 2007; 3: 270–278.

    PubMed  Google Scholar 

  72. Krinsley JS . Glycemic control in the critically ill: what have we learned since NICE-SUGAR? Hosp Pract (1995) 2015; 43: 191–197.

    Google Scholar 

  73. Van den Berghe G, Schetz M, Vlasselaers D, Hermans G, Wilmer A, Bouillon R et al. Clinical review: Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? J Clin Endocrinol Metab 2009; 94: 3163–3170.

    CAS  PubMed  Google Scholar 

  74. Dandona P, Chaudhuri A, Ghanim H, Mohanty P . Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose. Semin Thorac Cardiovasc Surg 2006; 18: 293–301.

    PubMed  Google Scholar 

  75. Marik PE, Preiser JC . Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. Chest 2010; 137: 544–551.

    CAS  PubMed  Google Scholar 

  76. Fuji S, Kim SW, Mori S, Kamiya S, Yoshimura K, Yokoyama H et al. Intensive glucose control after allogeneic hematopoietic stem cell transplantation: a retrospective matched-cohort study. Bone Marrow Transplant 2009; 44: 105–111.

    CAS  PubMed  Google Scholar 

  77. Queale WS, Seidler AJ, Brancati FL . Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med 1997; 157: 545–552.

    CAS  PubMed  Google Scholar 

  78. Krinsley JS . Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008; 36: 3008–3013.

    CAS  PubMed  Google Scholar 

  79. Asudani D, Calles-Escandon J . Inpatient hyperglycemia: slide through the scale but cover the bases first. J Hosp Med 2007; 2 (Suppl 1): 23–32.

    PubMed  Google Scholar 

  80. Hirsch IB . Sliding scale insulin—time to stop sliding. JAMA 2009; 301: 213–214.

    CAS  PubMed  Google Scholar 

  81. Michota F . What are the disadvantages of sliding-scale insulin? J Hosp Med 2007; 2 (Suppl 1): 20–22.

    PubMed  Google Scholar 

  82. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011; 34: 256–261.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Umpierrez G, Cardona S, Pasquel F, Jacobs S, Peng L, Unigwe M et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. Diabetes Care 2015; 38: 1665–1672.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Olveira G, Tapia MJ, Ocon J, Cabrejas-Gomez C, Ballesteros-Pomar MD, Vidal-Casariego A et al. Parenteral nutrition-associated hyperglycemia in non-critically ill inpatients increases the risk of in-hospital mortality (multicenter study). Diabetes Care 2013; 36: 1061–1066.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Sheean P, Braunschweig C . The incidence and impact of dextrose dose on hyperglycemia from parenteral nutrition (PN) exposure in hematopoietic stem cell transplant (HSCT) recipients. JPEN J Parenter Enteral Nutr 2006; 30: 345–350.

    PubMed  Google Scholar 

  86. Sheean PM, Braunschweig C, Rich E . The incidence of hyperglycemia in hematopoietic stem cell transplant recipients receiving total parenteral nutrition: a pilot study. J Am Diet Assoc 2004; 104: 1352–1360.

    PubMed  Google Scholar 

  87. Mirtallo J, Canada T, Johnson D, Kumpf V, Petersen C, Sacks G et al. Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr 2004; 28: S39–S70.

    PubMed  Google Scholar 

  88. Lenssen P, Aker S. Nutrition support of the hematopoietic cell transplant recipient. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds). Thomas' Hematopoietic Cell Transplantation. Wiley-Blackwell: Oxford, UK, 2009, pp 1551–1569.

  89. Muscaritoli M, Conversano L, Torelli GF, Arcese W, Capria S, Cangiano C et al. Clinical and metabolic effects of different parenteral nutrition regimens in patients undergoing allogeneic bone marrow transplantation. Transplantation 1998; 66: 610–616.

    CAS  PubMed  Google Scholar 

  90. Lenssen P, Bruemmer BA, Bowden RA, Gooley T, Aker SN, Mattson D . Intravenous lipid dose and incidence of bacteremia and fungemia in patients undergoing bone marrow transplantation. Am J Clin Nutr 1998; 67: 927–933.

    CAS  PubMed  Google Scholar 

  91. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 2014; 37 (Suppl 1): S14–S80.

    Google Scholar 

  92. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 2015; 21: 1–87.

    PubMed  PubMed Central  Google Scholar 

  93. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2013; 36: 3821–3842.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Chow EJ, Baker KS, Lee SJ, Flowers ME, Cushing-Haugen KL, Inamoto Y et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol 2014; 32: 191–198.

    PubMed  Google Scholar 

  95. Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM et al. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA Intern Med 2014; 174: 1955–1962.

    PubMed  Google Scholar 

  96. American Diabetes Association. (7) Approaches to glycemic treatment. Diabetes Care 2015; 38: S41–S48.

    Google Scholar 

  97. Meah F, Juneja R . Insulin tactics in type 2 diabetes. Med Clin North Am 2015; 99: 157–186.

    PubMed  Google Scholar 

  98. Wesorick D, O'Malley C, Rushakoff R, Larsen K, Magee M . Management of diabetes and hyperglycemia in the hospital: a practical guide to subcutaneous insulin use in the non-critically ill, adult patient. J Hosp Med 2008; 3 (5 Suppl): 17–28.

    PubMed  Google Scholar 

  99. Lovre D, Fonseca V . Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complications 2015; 29: 295–301.

    PubMed  Google Scholar 

  100. Jenssen T, Hartmann A . Prevention and management of transplant-associated diabetes. Expert Opin Pharmacother 2011; 12: 2641–2655.

    CAS  PubMed  Google Scholar 

  101. Gilbert RE, Krum H . Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015; 385: 2107–2117.

    CAS  PubMed  Google Scholar 

  102. Billington EO, Grey A, Bolland MJ . The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia 2015; 58: 2238–2246.

    CAS  PubMed  Google Scholar 

  103. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427–2443.

    CAS  PubMed  Google Scholar 

  104. Mikhail N . Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Saf 2011; 6: 304–309.

    CAS  PubMed  Google Scholar 

  105. Ahren B . Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes. World J Diabetes 2014; 5: 40–51.

    PubMed  PubMed Central  Google Scholar 

  106. O'Leary H, Ou X, Broxmeyer HE . The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. Curr Opin Hematol 2013; 20: 314–319.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. El Ghandour S, Azar S . Incretin based therapy in the management of steroid induced diabetes mellitus. Curr Diabetes Rev 2014; 10: 360–363.

    CAS  PubMed  Google Scholar 

  108. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M . Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011; 34: 412–417.

    CAS  PubMed  PubMed Central  Google Scholar 

  109. Halimi S, Verges B . Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab 2014; 40 (Suppl 1): S28–S34.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by Foundation for Promotion of Cancer Research in Japan. This work was also supported by the National Institutes of Health/National Heart, Lung, and Blood Institute Grant 1K23HL122143-01A (to BGE).

Author information

Author notes

  1. S Fuji and A Rovó: These authors contributed equally as first authors.

  2. A Tichelli and B N Savani: These authors contributed equally as senior authors.

Authors and Affiliations

  1. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

    S Fuji

  2. Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany

    S Fuji, H Einsele & M Kapp

  3. Department of Hematology, University Hospital of Bern, Bern, Switzerland

    A Rovó

  4. Department of General Medicine, National Cancer Center Hospital, Tokyo, Japan

    K Ohashi

  5. Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

    M Griffith

  6. Department of Haematology, Saint Antoine Hospital, Paris, France

    M Mohty

  7. Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, OH, USA

    N S Majhail

  8. Division of Hematology/Oncology, Department of Medicine, Hematology and Stem Cell Transplantation Section, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA

    B G Engelhardt & B N Savani

  9. Department of Internal Medicine, Division of Hematology, University Hospital Basel, Basel, Switzerland

    A Tichelli

Authors
  1. S Fuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Rovó
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Griffith
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Einsele
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Kapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N S Majhail
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B G Engelhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Tichelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B N Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Fuji.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fuji, S., Rovó, A., Ohashi, K. et al. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. Bone Marrow Transplant 51, 1041–1049 (2016). https://doi.org/10.1038/bmt.2016.81

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.81

This article is cited by

Search

Advanced search

Quick links